Cargando…
The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment
Non-small cell lung cancer (NSCLC) is a prominent etiology of cancer-related mortality. The heterogeneous nature of this disease impedes its accurate diagnosis and efficacious treatment. Consequently, constant advancements in research are imperative in order to comprehend its intricate nature. In ad...
Autores principales: | Peng, Lei, Xu, Quan, Yin, Sui, Zhang, Ye, Wu, Hao, Liu, Yangchun, Chen, Liru, Hu, Yeji, Yuan, Jun, Peng, Kai, Lin, Qin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172578/ https://www.ncbi.nlm.nih.gov/pubmed/37182180 http://dx.doi.org/10.3389/fonc.2023.1153319 |
Ejemplares similares
-
Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015) -
Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019) -
Editorial: Challenges, techniques and pitfalls in surgery: How far can we push the boundaries?
por: Cianci, S., et al.
Publicado: (2022) -
Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?
por: Patel, Aditi, et al.
Publicado: (2022) -
Look how far we have come: BREAST cancer detection education on the international stage
por: Trieu, Phuong Dung (Yun), et al.
Publicado: (2023)